11
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      L3MBTL1 Regulates ALS/FTD-associated Proteotoxicity and Quality Control

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Misfolded protein toxicity and failure of protein quality control underlie neurodegenerative diseases including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Here, we identified Lethal(3)malignant brain tumor-like protein 1 (L3MBTL1) as a previously unknown regulator of protein quality control, the loss of which protected against the proteotoxicity of mutant SOD1 or C9orf72 dipeptide repeat proteins. L3MBTL1 acts by regulating p53-dependent quality control systems that degrade misfolded proteins. SET domain-containing protein 8 (SETD8), a L3MBTL1-associatd p53-binding protein, also regulated clearance of misfolded proteins and was increased by proteotoxicity-associated stresses in mammalian cells. Both L3MBTL1 and SETD8 were up-regulated in the central nervous systems of mouse models of ALS and human ALS/FTD patients. The role of L3MBTL1 in protein quality control is conserved from C. elegans to mammalian neurons. These results indicate a previously unrecognized pathway in both normal stress response and proteotoxicity-associated neurodegenerative diseases.

          Related collections

          Most cited references27

          • Record: found
          • Abstract: found
          • Article: not found

          Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation.

          Mutations of human Cu,Zn superoxide dismutase (SOD) are found in about 20 percent of patients with familial amyotrophic lateral sclerosis (ALS). Expression of high levels of human SOD containing a substitution of glycine to alanine at position 93--a change that has little effect on enzyme activity--caused motor neuron disease in transgenic mice. The mice became paralyzed in one or more limbs as a result of motor neuron loss from the spinal cord and died by 5 to 6 months of age. The results show that dominant, gain-of-function mutations in SOD contribute to the pathogenesis of familial ALS.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention.

            A hexanucleotide GGGGCC repeat expansion in the noncoding region of the C9ORF72 gene is the most common genetic abnormality in familial and sporadic amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The function of the C9ORF72 protein is unknown, as is the mechanism by which the repeat expansion could cause disease. Induced pluripotent stem cell (iPSC)-differentiated neurons from C9ORF72 ALS patients revealed disease-specific (1) intranuclear GGGGCCexp RNA foci, (2) dysregulated gene expression, (3) sequestration of GGGGCCexp RNA binding protein ADARB2, and (4) susceptibility to excitotoxicity. These pathological and pathogenic characteristics were confirmed in ALS brain and were mitigated with antisense oligonucleotide (ASO) therapeutics to the C9ORF72 transcript or repeat expansion despite the presence of repeat-associated non-ATG translation (RAN) products. These data indicate a toxic RNA gain-of-function mechanism as a cause of C9ORF72 ALS and provide candidate antisense therapeutics and candidate human pharmacodynamic markers for therapy. Copyright © 2013 Elsevier Inc. All rights reserved.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Short-lived green fluorescent proteins for quantifying ubiquitin/proteasome-dependent proteolysis in living cells.

              The ubiquitin/proteasome-dependent proteolytic pathway is an attractive target for therapeutics because of its critical involvement in cell cycle progression and antigen presentation. However, dissection of the pathway and development of modulators are hampered by the complexity of the system and the lack of easily detectable authentic substrates. We have developed a convenient reporter system by producing N-end rule and ubiquitin fusion degradation (UFD)-targeted green fluorescent proteins that allow quantification of ubiquitin/proteasome-dependent proteolysis in living cells. Accumulation of these reporters serves as an early predictor of G2/M arrest and apoptosis in cells treated with proteasome inhibitors. Comparison of reporter accumulation and cleavage of fluorogenic substrates demonstrates that the rate-limiting chymotrypsin-like activity of the proteasome can be substantially curtailed without significant effect on ubiquitin-dependent proteolysis. These reporters provide a new powerful tool for elucidation of the ubiquitin/proteasome pathway and for high throughput screening of compounds that selectively modify proteolysis in vivo.
                Bookmark

                Author and article information

                Journal
                9809671
                21092
                Nat Neurosci
                Nat. Neurosci.
                Nature neuroscience
                1097-6256
                1546-1726
                23 May 2019
                06 May 2019
                June 2019
                06 November 2019
                : 22
                : 6
                : 875-886
                Affiliations
                [1 ]Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA
                [2 ]Department of Neuroscience, School of Medicine, Johns Hopkins University, Baltimore, MD, USA
                [3 ]Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
                Author notes
                [†]

                These authors contributed equally to this work.

                Author Contributions

                J.L. performed the C. elegans suppressor screen, genome deep-sequencing and data analysis, and the characterization of the C. elegans suppressor mutations. J.L. and G.P. performed most of the mammalian cell experiments. G.P. and Y.N.L. performed the Drosophila experiments. Q.T., J.M., and R.K. performed the mammalian neuronal experiments. Y.S., R.T., R.A., and W.L. performed the mouse experiments. Y.N.L. and Y.L. performed the mouse and human tissue analysis. T.Z., Y.J., and K.J. performed additional experiments. G.P., J.L., Y.N.L., and J.W. designed the studies and wrote the paper. All authors discussed the results and contributed to the preparation of the manuscript.

                [* ]To whom correspondence should be addressed: Jiou Wang, Department of Biochemistry and Molecular Biology, The Johns Hopkins University, 615 N. Wolfe Street, E8410, Baltimore, MD 21205 USA Phone: (410) 502-0927 Fax: (410) 955-2926, jiouw@ 123456jhmi.edu
                Article
                NIHMS1523941
                10.1038/s41593-019-0384-5
                6588399
                31061493
                2a19e4b9-6b4c-4b0c-9a3f-06ff83aa6ed6

                Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms

                History
                Categories
                Article

                Neurosciences
                als,ftd,l3mbtl1,neurodegeneration,proteotoxicity,setd8
                Neurosciences
                als, ftd, l3mbtl1, neurodegeneration, proteotoxicity, setd8

                Comments

                Comment on this article